JSPR news

Jasper Therapeutics has completed the enrollment of the first IgAN cohort of its Phase 2 study evaluating vensobafusp alfa. The company anticipates reporting initial interim data by year-end 2026 and plans to accelerate an expansion cohort in FSGS patients in early 2027.

The Company is offering to purchase any and all outstanding warrants in an attempt to reduce dilution and set a clear capital structure, with the purchase price at $0.324 per warrant.

Jasper Therapeutics and Kira Pharmaceuticals have entered into a merger agreement. This transaction is intended to combine their oncology capabilities and advance pipeline development.

Jasper Therapeutics announced the completion of an all-stock merger with Kira Pharmaceuticals and a concurrent $132 million private placement. This transaction combines pipelines for complement therapies and secures funding to support operations through the second half of 2028.

Jasper Therapeutics initiated a comprehensive review of strategic alternatives to maximize shareholder value, including potential asset sales, licensing, collaborations, company sale, or orderly wind-down. The clinical-stage biotech company is evaluating cost-saving measures while maintaining regula…